Evidence map›Paper›PMID 31379734›Full record

ArticleFrontiers in endocrinology2019

Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.

Maria Fleseriu, Chioma Iweha, Luiz Salgado, Tania Longo Mazzuco, Federico Campigotto, Ricardo Maamari, Padiporn Limumpornpetch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Maria FleseriuDepartments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health and Science University, Portland, OR, United States.
Chioma IwehaPanda Medical Associates, Peoria, AZ, United States.
Luiz SalgadoGeneral Internal Medicine Service, Hospital das Clinicas da Faculdade de Medicina FMUSP, São Paulo, Brazil.
Tania Longo MazzucoDivision of Endocrinology of Medical Clinical Department, University Hospital, UEL, Londrina, Brazil.
Federico CampigottoNovartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Ricardo MaamariNovartis Pharmaceuticals Corporation, East Hanover, NJ, United States.
Padiporn LimumpornpetchDivision of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.
Novartis (United States) · USHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRMedical Research Associates · USNeurological Surgery · USPrince of Songkla University · THUniversidade Estadual de Londrina · BR

Funding

Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)UL1TR002369 · NCATS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Cynthia D Morris, Christopher G. Slatore · 2017 to 2026
$78.4M
NCATS NIH HHS UL1 TR002369
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical practiceCushing's diseasepasireotide screal worldsomatostatin analog

Identifiers

PMID31379734
PMCPMC6646464
OpenAlexW2951461049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.